You are here
Open
NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.
If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).
-
A244-P037: Artificial Intelligence/ Machine Learning (AI/ML) Focused Open Topic
Release Date: 10-03-2023Open Date: 06-10-2024Due Date: 03-31-2025Close Date: 09-16-2024OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Trusted AI and Autonomy; Advanced Computing and Software OBJECTIVE: The purpose of the AI/ML Focused Open Topic is to bring potentially valuable small business innovations to the Army and create an opportunity to expand the relevance of the Army SBIR program to firms who do not normally compete for SBIR awards. DESCRIPTION: This open topic accepts bo ...
SBIRPhase I/Phase IIDepartment of DefenseArmy -
A244-P038: Hybrid Electric Powertrain, Power, and Propulsion Systems (HEPPS) Open Topic
Release Date: 10-03-2023Open Date: 06-10-2024Due Date: 03-31-2025Close Date: 09-16-2024OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Advanced Materials; Advanced Computing and Software OBJECTIVE: The purpose of the Hybrid Electric Powertrain, Power, and Propulsion Systems (HEPPS) Open Topic is to bring potentially valuable small business innovations to the Army and create an opportunity to expand the relevance of the Army SBIR program to firms who do not normally compete for SBIR awar ...
SBIRPhase I/Phase IIDepartment of DefenseArmy -
A244-027: xTechSpecial Forces
Release Date: 10-03-2023Open Date: 04-30-2024Due Date: 03-31-2025Close Date: 10-21-2024OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Trusted AI and Autonomy; Advanced Computing and Software; Integrated Sensing and Cyber; Microelectronics; Integrated Network Systems-of-Systems; Advanced Materials; Human-Machine Interfaces OBJECTIVE: Topic 1: GPS Denied ATAK Compatible Self Location Application The US Army 1st Special Forces Command (Airborne) is seeking a software solution to obt ...
SBIRPhase I/Phase IIDepartment of DefenseArmy -
A244-P017: xTechScalable AI 2
Release Date: 10-03-2023Open Date: 03-11-2024Due Date: 03-31-2025Close Date: 11-18-2024OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Artificial Intelligence/ Machine Learning; Trusted AI and Autonomy; Advanced Computing and Software; Human-Machine Interfaces OBJECTIVE: Topic 1: Scalable Tools for Automated AI Risk Management and Algorithmic Analysis As the Army deploys Artificial Intelligence (AI) systems, there is an inherent risk that the AI model could fail to perform as expe ...
SBIRPhase I/Phase IIDepartment of DefenseArmy -
RFA-DA-25-049: Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42- Clinical Trial Optional)
Release Date: 06-13-2024Open Date: 11-02-2024Due Date: 12-02-2024Close Date: 12-03-2024Background Non-disordered drug use is defined as using a substance in the past year without meeting two or more Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) diagnostic criteria for a substance use disorder (SUD). Non-disordered drug use can have negative health consequences, including, but not limited to, an increased risk of drug (e.g., opioid, cannabis, synthetic ...
STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-DA-25-050: Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44- Clinical Trial Optional)
Release Date: 06-13-2024Open Date: 11-02-2024Due Date: 12-02-2024Close Date: 12-03-2024Background Non-disordered drug use is defined as using a substance in the past year without meeting two or more Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) diagnostic criteria for a substance use disorder (SUD). Non-disordered drug use can have negative health consequences, including, but not limited to, an increased risk of drug (e.g., opioid, cannabis, synthetic ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
PAR-22-102: Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional)
Release Date: 01-21-2022Open Date: 02-28-2022 Due Dates: Multiple Close Date: 12-05-2024Background Currently, there are only three medications (four formulations) approved by the FDA for the treatment of alcohol use disorder (AUD). The need for additional medications to treat those affected by AUD is urgently needed.In addition,alcohol misuseaffects virtually all tissues and is linked with dysfunction and failure of many organs and systems including the liver, heart, pancreas, lung, ...
STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
PAR-22-103: Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional)
Release Date: 01-21-2022Open Date: 02-28-2022 Due Dates: Multiple Close Date: 12-05-2024Background Currently, there are only three medications (four formulations) approved by the FDA for the treatment of alcohol use disorder (AUD). The need for additional medications to treat those affected by AUD is urgently needed.In addition,alcohol misuseaffects virtually all tissues and is linked with dysfunction and failure of many organs and systems including the liver, heart, pancreas, lung, ...
STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-DA-23-021: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44- Clinical Trial Optional)
Release Date: 03-28-2022Open Date: 07-15-2022 Due Dates: Multiple Close Date: 02-15-2025According to the Centers for Disease Control and Prevention (CDC), more than 100,000 deaths from overdose were reported from April 2020 to April 2021 alone. Data shows an increase in overdoses due to natural and semi-synthetic opioids, synthetic opioids, predominantly fentanyl, and psychostimulants, such as methamphetamine or cocaine. In fact, in the year ending in April 2021, fentanyl was the lea ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-DA-24-038: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
Release Date: 04-19-2023Open Date: 07-15-2023 Due Dates: Multiple Close Date: 02-15-2025According to the Centers for Disease Control and Prevention (CDC), more than 100,000 deaths from overdose were reported from April 2020 to April 2021 alone. Data shows an increase in overdoses due to natural and semi-synthetic opioids, synthetic opioids, predominantly fentanyl, and psychostimulants, such as methamphetamine or cocaine. In fact, in the year ending in April 2021, fentanyl was the lea ...
STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
